Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

60 Degrees Pharmaceuticals Inc (SXTP)

60 Degrees Pharmaceuticals Inc (SXTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,581
  • Shares Outstanding, K 4,230
  • Annual Sales, $ 680 K
  • Annual Income, $ -7,950 K
  • EBIT $ -8 M
  • EBITDA $ -4 M
  • 60-Month Beta 2.98
  • Price/Sales 1.20
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.47
  • Most Recent Earnings $-0.66 on 11/13/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.57
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -0.64
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3400 +79.41%
on 01/14/26
0.8731 -30.13%
on 12/18/25
-0.2199 (-26.50%)
since 12/16/25
3-Month
0.3400 +79.41%
on 01/14/26
1.5601 -60.90%
on 10/20/25
-0.8900 (-59.33%)
since 10/16/25
52-Week
0.3400 +79.41%
on 01/14/26
6.0000 -89.83%
on 01/29/25
-3.5170 (-85.22%)
since 01/16/25

Most Recent Stories

More News
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA ® ( tafenoquine ) for treatment of chronic babesiosis Data support theory among specialists that Babesia...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip...

PCSA : 3.54 (-4.58%)
SXTP : 0.6100 (+31.01%)
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

6-month commercial pilot demonstrated increasing demand among prescribers Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign ...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

90-day trial will measure change in general fatigue in patients with chronic babesiosis following  tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Q3 2025 net product revenue increased 223% year-over-year to $438 thousand Gross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)
60 Degrees Pharmaceuticals and NDT Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / October 31, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip...

SXTP : 0.6100 (+31.01%)
NDTP : 1.1500 (-11.54%)
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) Results...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)
60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. 60 Degrees...

SXTP : 0.6100 (+31.01%)
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning...

SXTP : 0.6100 (+31.01%)
SXTPW : 0.0598 (+8.73%)

Business Summary

60 Degrees Pharmaceuticals Inc. specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. 60 Degrees Pharmaceuticals Inc. is based in WASHINGTON.

See More

Key Turning Points

3rd Resistance Point 0.9085
2nd Resistance Point 0.7928
1st Resistance Point 0.7014
Last Price 0.6100
1st Support Level 0.4943
2nd Support Level 0.3786
3rd Support Level 0.2872

See More

52-Week High 6.0000
Fibonacci 61.8% 3.8379
Fibonacci 50% 3.1700
Fibonacci 38.2% 2.5021
Last Price 0.6100
52-Week Low 0.3400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar